Rationale and design of INFINITY-SWEDEHEART: A registry-based randomized clinical trial comparing clinical outcomes of the sirolimus-eluting DynamX bioadaptor to the zotarolimus-eluting Resolute Onyx stent
David Erlinge(Lund University), Stefan James(Uppsala University), Felix Böhm(Karolinska University Hospital), Jonas Andersson(Skellefteå Hospital), Jonas Oldgren(Uppsala University), Claes Held(Uppsala University), Candace Elek(Elixir Medical (United States)), Mattias Törnerud(Karolinska Institutet), Motasim Sirhan(Elixir Medical (United States)), Ole Fröbert(Aarhus University)
Cited by 5
Related Papers
Dabigatran versus Warfarin in Patients with Atrial Fibrillation
|New England Journal of Medicine|2009|11.2k
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
|New England Journal of Medicine|2009|7.1k
ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation
|European Heart Journal|2012|6.8k
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
|New England Journal of Medicine|2019|6.8k
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS
|European Heart Journal|2017|3k